KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) FCF Margin (2016 - 2025)

Historic FCF Margin for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to 26.52%.

  • Acadia Pharmaceuticals' FCF Margin rose 12900.0% to 26.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 18.92%, marking a year-over-year decrease of 28900.0%. This contributed to the annual value of 16.41% for FY2024, which is 141200.0% up from last year.
  • Acadia Pharmaceuticals' FCF Margin amounted to 26.52% in Q3 2025, which was up 12900.0% from 24.17% recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' FCF Margin ranged from a high of 36.96% in Q4 2023 and a low of 66.1% during Q1 2022
  • For the 5-year period, Acadia Pharmaceuticals' FCF Margin averaged around 4.26%, with its median value being 0.56% (2022).
  • Examining YoY changes over the last 5 years, Acadia Pharmaceuticals' FCF Margin showed a top increase of 544400bps in 2023 and a maximum decrease of -272900bps in 2023.
  • Acadia Pharmaceuticals' FCF Margin (Quarter) stood at 17.68% in 2021, then grew by 1bps to 17.48% in 2022, then skyrocketed by 311bps to 36.96% in 2023, then crashed by -58bps to 15.38% in 2024, then surged by 72bps to 26.52% in 2025.
  • Its FCF Margin stands at 26.52% for Q3 2025, versus 24.17% for Q2 2025 and 8.32% for Q1 2025.